Y2K Compliance Plans Should Be Available For FDA Review - Woodcock
This article was originally published in The Tan Sheet
Executive Summary
Details of pharmaceutical companies' efforts to deal with potential year 2000 (Y2K) problems should be "available for FDA review," Center for Drug Evaluation & Research Director Janet Woodcock, MD, states in an Oct. 14 letter to drug associations.